Living Cell shares rise as company completes first trial for Parkinson's treatment

Living Cell shares rise as company completes first trial for Parkinson's treatment
Fiona Rotherham
By Fiona Rotherham Oct. 5 (BusinessDesk) - Shares of Australasian biotech company Living Cell Technologies rose 7.4 percent to 8.7 Australian cents on the ASX today after it announced the completion of the first stage of a clinical trial underway in Auckland of its planned treatment for Parkinson’s disease. The shares have bounced around a range of 4-to-11 Australian cents this year as the company awaits next year's outcome of the Phase 11b clinical trial of NTCELL, which would be the world’s first disease-modifying treatment for Parkinso...